Navigation Links
Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
Date:10/24/2007

BERKELEY HEIGHTS, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that clinical data from the Company's programs for Genasense(R) (oblimersen) in patients with advanced melanoma will be featured at the 4th International Melanoma Congress. The conference will take place at the New York Marriott Financial Center Hotel, New York, NY from November 1-4, 2007. A poster session featuring the Genasense data will take place on Thursday November 1 from 8-10 am EDT.

Titles and authors include the following:

Progression-free survival (PFS) with an oblimersen-dacarbazine regimen in advanced melanoma: PFS difference is not explained by assessment asymmetry. Presenter: E. Gilles.

Overview of the AGENDA Study: A randomized, double-blind study of Genasense plus dacarbazine in chemotherapy-naive patients with advanced melanoma and low LDH. Presenter: A. Bedikian.

A Phase I study of the triple combination of oblimersen, temozolomide, and Abraxane in patients with advanced melanoma and normal LDH. Presenter: A. Pavlick.

Pharmacokinetics of oblimersen in combination with dacarbazine in metastatic melanoma: randomized intra-subject evaluation. Presenter: D. Kerob.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversif
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... MONROVIA, Calif. , Sept. 2, 2015 STAAR ... and marketer of implantable lenses and delivery systems for the ... William P. Wall to the Company,s Board. ... Abrams Capital, a Boston -based investment firm, ... member of the Board of Directors, and chair of the ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has ... China (Basel, Switzerland - November 26-27, 2015)" conference to ... detailed overview of the key areas of pharmaceutical regulatory affairs ... , Macau and ... All important aspects of gaining and maintaining a successful Marketing ...
(Date:9/2/2015)... , Sept. 2, 2015 Amgen ... of a Marketing Authorization Application (MAA) to the ... for etelcalcetide (formerly AMG 416) for the treatment ... chronic kidney disease (CKD) on hemodialysis therapy. If ... that can be administered intravenously. Etelcalcetide ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7
...   Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: ... wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") ... a marketing and distribution agreement with Asian American ... to distribute and sell Clotamin in 1,200 AACSA ...
... Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel ... has completed its previously announced sale of an aggregate ... warrants to purchase an additional 2,512,500 shares of common ... share.  The total gross proceeds from the registered direct ...
Cached Medicine Technology:Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores 2Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores 3Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering 2Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering 3
(Date:9/3/2015)... NC (PRWEB) , ... September 03, 2015 , ... ... August 31, 2015: DiabetesSisters is pleased to announce the additional of Carol Wysham, ... 2015 by current board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the complete ... Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... responsibilities which can impact the delicate life balance between work and leisure to ... - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® Emergency Care Document Set ...
(Date:9/3/2015)... ... September 03, 2015 , ... AvePoint, the established leader in ... Pack (SP) 4 – AvePoint’s solution for facilitating two-way collaboration and external sharing ... Trend-Setting Product”. This is the fifth consecutive year an AvePoint product has made ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mum n Me is pleased to announce the ... extra-large size that gives maximum protection from sun exposure, wind, bugs, and germs. The ... deliver non-slip assurance by keeping the cover securely in place. The new car seat ...
Breaking Medicine News(10 mins):Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:Mum n Me Announces New Baby Car Seat Cover 2
... a colourless, odourless and tasteless chemical element - could ... ,Patients with chronic obstructive pulmonary disease (COPD) have ... the lungs at the end of each breath. This ... reasons for shortness of breath experienced by these patients, ...
... Here’s the good news, the bad news, and some more ... Americans, according to one recent study) are satisfied// with their ... way of having a good sex life, from prescription medication ... ,In many cases, physicians can work with their patients to ...
... Andhra Pradesh and Tamil Nadu will upgrade their existing ... ,"It has been decided to upgrade the hospitals in ... Vice Admiral surgeon Vijay K. Singh, director general of ... ,Singh said a Rs.3-billion budget has been sanctioned, ...
... one in three children in California is overweight or at ... health insurance company.// ,There are even more ... satellite cities. ,The number of overweight children ... rest of California, and nearly doubles the national rate, said ...
... Jammu and Kashmir by humanitarian group Médecins Sans Frontières (MSF) ... and more than one in 10 had been victims of ... ,The report by the Holland-based MSF is based on ... in mid-2005. The survey group defined 1989 as the beginning ...
... have made a Startling discovery. The researchers who want ... their intake of calories is restricted have found that ... on longevity in the fruit flies. ,Scientists ... increase the lifespan of many species, but the mechanism ...
Cached Medicine News:Health News:Helium Helps COPD Sufferers to Exercise 2Health News:Health Issues That Can Impact Sexual Satisfaction 2Health News:Health Issues That Can Impact Sexual Satisfaction 3Health News:Health Issues That Can Impact Sexual Satisfaction 4Health News:South India to Have Modern Military Hospitals 2Health News:Mental Health of Kashmiris Needs Urgent Attention: Survey 2Health News:Food Odors Linked With Lifespan in Fruit Flies 2Health News:Food Odors Linked With Lifespan in Fruit Flies 3Health News:Food Odors Linked With Lifespan in Fruit Flies 4Health News:Food Odors Linked With Lifespan in Fruit Flies 5
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... Deviation Splint uses safe, mild to moderate ... deviation at the MP joints. Dorsal-based splint ... and ulnar polycentric hinges located at the ... Padded, malleable finger rings can be individually ...
Medicine Products: